CuraCell announces first patient included in clinical trial of innovative TIL therapy CC-38

First patient has been successfully included in the ongoing phase I/IIa clinical trial evaluating CuraCell’s autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer.

Read the full article